QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)

Provention Bio (PRVB) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$24.98
$25.00
50-Day Range
$23.74
$24.98
52-Week Range
$3.18
$25.00
Volume
9.12 million shs
Average Volume
2.28 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.83

Provention Bio MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
8.6% Downside
$22.83 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$53.27 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.72) to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

851st out of 981 stocks

Pharmaceutical Preparations Industry

403rd out of 464 stocks


PRVB stock logo

About Provention Bio (NASDAQ:PRVB) Stock

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Sanofi completes Provention Bio acquisition
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
PRVB Apr 2023 23.000 put
Q4 2022 MacroGenics Inc Earnings Call
Provention Bio's Earnings Outlook
Short Volatility Alert: Provention Bio Inc
4 Analysts Have This to Say About Provention Bio
See More Headlines


PRVB Company Calendar

Last Earnings
3/29/2023
Today
6/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRVB
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.83
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
-8.6%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-113,570,000.00
Net Margins
-880.69%
Pretax Margin
-984.54%

Debt

Sales & Book Value

Annual Sales
$12.90 million
Book Value
$1.40 per share

Miscellaneous

Free Float
82,365,000
Market Cap
$2.37 billion
Optionable
Not Optionable
Beta
2.47

Key Executives

  • Ashleigh W. PalmerAshleigh W. Palmer
    Chief Executive Officer & Director
  • Christina Yi
    Chief Operating Officer
  • Thierry Chauche
    Chief Financial Officer
  • Francisco LeonFrancisco Leon
    Chief Scientific Officer
  • Eleanor Leni Ramos
    Chief Medical Officer













PRVB Stock - Frequently Asked Questions

Should I buy or sell Provention Bio stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PRVB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRVB, but not buy additional shares or sell existing shares.
View PRVB analyst ratings
or view top-rated stocks.

What is Provention Bio's stock price forecast for 2023?

7 Wall Street research analysts have issued 1-year price objectives for Provention Bio's shares. Their PRVB share price forecasts range from $18.00 to $25.00. On average, they expect the company's stock price to reach $22.83 in the next year. This suggests that the stock has a possible downside of 8.6%.
View analysts price targets for PRVB
or view top-rated stocks among Wall Street analysts.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) announced its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.07. The business earned $10.81 million during the quarter, compared to analysts' expectations of $7.23 million. Provention Bio had a negative net margin of 880.69% and a negative trailing twelve-month return on equity of 103.36%.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sessa Capital IM L.P. (9.37%), BlackRock Inc. (5.98%), State Street Corp (1.83%), Geode Capital Management LLC (1.52%), Water Island Capital LLC (1.01%) and Pictet Asset Management SA (0.81%). Insiders that own company stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, Jason Hoitt and Sessa Capital (Master), LP.
View institutional ownership trends
.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $24.98.

How much money does Provention Bio make?

Provention Bio (NASDAQ:PRVB) has a market capitalization of $2.37 billion and generates $12.90 million in revenue each year. The company earns $-113,570,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com.

This page (NASDAQ:PRVB) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -